New generation ALK-inhibitors burden in lung cancer patients cardiovascular health: analysis from real world data
Rocío Aguado(Hospital Universitario Puerta de Hierro Majadahonda), Mariano Provencio(Hospital Universitario Puerta de Hierro Majadahonda), Yago Garitaonaindía(Copenhagen University Hospital), Marı́a José Blanco(Hospital Universitario Puerta de Hierro Majadahonda), Javier Segovia(Clinica Universidad de Navarra), Cristina Mitroi(Hospital Universitario Puerta de Hierro Majadahonda), M. Martínez(Hospital Universitario Puerta de Hierro Majadahonda), Ana Collazo(Hospital Universitario Puerta de Hierro Majadahonda), Aylen Vanessa Ospina(Hospital Universitario Puerta de Hierro Majadahonda)
Cited by 1
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Genetic Variants Associated With Cancer Therapy–Induced Cardiomyopathy
|Circulation|2019|346
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition
|Free Radical Biology and Medicine|2019|215
Ventricular Arrhythmias Among Implantable Cardioverter-Defibrillator Recipients for Primary Prevention
|Circulation Arrhythmia and Electrophysiology|2011|152